Dihexa

An AngIV analog identified as Dihexa improved selected motor and cognitive measures in a toxin-induced rat model.

Dihexa improved selected behavioral and neuropathologic measures in a transgenic mouse Alzheimer model.

Dihexa reduced aminoglycoside-associated hair-cell loss in a zebrafish lateral-line model through HGF/c-Met-related signaling.

Dihexa bound HGF and potentiated HGF-dependent c-Met signaling; synaptogenic and procognitive effects in experimental systems depended on this pathway.

Metabolically stabilized AngIV analogs, including Dihexa, improved performance in rodent models of cognitive impairment and increased synaptic connectivity markers.

Dihexa has been studied in zebrafish hair-cell injury and other laboratory systems. Protective effects were model-, toxin-, dose-, and pathway-specific and were not universal; preclinical c-Met activation must not be generalized into brain repair, hearing restoration, motor-neuron repair, or tissue regeneration.

In neuronal systems, Dihexa was associated with dendritic spine formation, synaptogenesis, and increased miniature excitatory postsynaptic current frequency, with effects blocked by HGF antagonism or c-Met suppression. These findings support an experimental HGF/c-Met-dependent mechanism and do not establish safe or beneficial human neurogenesis.

Orally administered Dihexa improved performance in the APP/PS1 Alzheimer-model mouse, a model-specific finding that does not establish treatment of Alzheimer disease, mild cognitive impairment, traumatic brain injury, Parkinson disease, or healthy aging.

Dihexa is a metabolically stabilized Angiotensin-IV-derived analogue distinct from native Angiotensin IV and Nle1-Angiotensin IV. Laboratory studies report that Dihexa binds HGF and potentiates HGF-dependent c-Met activation.

General trial-registry search portal used as part of this review's regulatory/trial-landscape check.

No FDA-approved Orexin A or Orexin B peptide drug or indication was identified in the reviewed FDA drug databases.

An FDA GSRS/UNII identity record is a substance-identification record, not drug approval.

FDA announced that Dihexa acetate is among substances intended for discussion by the Pharmacy Compounding Advisory Committee for possible 503A-list inclusion. Advisory review or nomination is not FDA approval, and no final favorable FDA determination was identified as of the research cutoff.

FDA states that it has not identified human exposure data for drug products containing Dihexa acetate administered by any route and lacks important information needed to determine whether it would harm humans.

Dihexa, also called PNB-0408, is the metabolically stabilized Angiotensin-IV-derived analogue N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) -- a small peptidomimetic/oligopeptide-derived molecule rather than a native endogenous peptide, distinct from Angiotensin IV, HGF, c-Met, HGF/c-Met agonist antibodies, fosgonimeton, and other unrelated compounds.